(PharmaNewsWire.Com, April 18, 2020 ) The miRNA sequencing and assay market is projected to reach USD 343 million by 2024 from USD 182 million in 2018, at a CAGR of 11.2%. Growth in this market is driven by factors such as the advantages of miRNA sequencing over other technologies, increasing research funding for genomics, and the decreasing cost of sequencing.
Sequencing consumables are projected to hold the largest share of the miRNA sequencing and assay market during the forecast period.
Based on product, the miRNA sequencing & assays market is segmented into library preparation kits and sequencing consumables. Sequencing consumables dominated the market with a larger share in 2018. The large share of this segment can primarily be attributed to the growing demand for consumables and increasing adoption of small RNA sequencing.
The research and academic institutes end-user segment held the largest share of the market in 2018
Based on end users, the miRNA sequencing & assays market is segmented into academic and research institutes and contract research organizations. In 2018, academic and research institutes accounted for the largest share of the miRNA sequencing & assays market. The large share of this segment can be attributed to the availability of research grants and the increasing focus of market players on providing efficient miRNA sequencing products and services for research applications.
North America dominated the miRNA sequencing and assay market in 2018
North America is estimated to account for the largest share of the market in 2018. Factors such as increasing investments in the development of sequencing, growing research in the fields of genomics and RNA biology, and the rising demand for economical, high-throughput techniques for miRNA analysis are driving the growth of the miRNA sequencing & assays market in this region.
Major vendors in the Microscope software market include Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Germany), Takara Bio (Japan), and NEB (UK), among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
